APAC’s biotechnology applications ready for multi-sector growth
The Asia Pacific biotech industry is anticipated to grow even faster, with a CAGR of 16.8 percent through 2028. Improvements in healthcare infrastructure , supporting government policies, clinical trial services , and epidemiological variables have all contributed to this rapid progress. Foreign firms are increasingly interested in working with or collaborating closely with local biotechnology firms. BIO Digital 2021, the world’s largest biotech partnership and education event was recently hosted in Taiwan. It was supported by the Taiwanese government and highlighted novel, locally created cancer medicines and cell treatments. This has piqued the interest of major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, and Merck, among others. Read more